Cancer treatment and research最新文献_第3页

Cancer Immunotherapy-An Overview. 癌症免疫治疗综述

Cancer treatment and research Pub Date : 2025-01-01 DOI: 10.1007/978-3-031-97242-3_1

Prakash Kulkarni, Dana Do, Sagun Shrestha, Benjamin Leach, Ravi Salgia

{"title":"Cancer Immunotherapy-An Overview.","authors":"Prakash Kulkarni, Dana Do, Sagun Shrestha, Benjamin Leach, Ravi Salgia","doi":"10.1007/978-3-031-97242-3_1","DOIUrl":"10.1007/978-3-031-97242-3_1","url":null,"abstract":"Immunotherapy has had a profound impact on how we treat cancer. Immunotherapy takes advantage of the body's immune system to combat the disease and is considered as one of the pillars of cancer care together with chemotherapy, radiation therapy, and surgery. This introductory chapter provides a brief overview of the different types of cancer immunotherapies currently available, their mechanisms of action, and the benefits and potential side effects. Despite the success of these emerging therapies, resistance remains a genuine concern. Thus, mechanisms of resistance to immunotherapy are also briefly discussed. In addition, an overview of the various combination therapies such as chemotherapy, radiation therapy, and targeted therapy, that are currently used in combination with cancer immunotherapy, is presented. Finally, the chapter highlights how a \"Team Medicine\" approach could enable all eligible cancer patients to receive this promising treatment to treat their respective cancer types. More, detailed information regarding the different immunotherapies as well as their combinations when applicable in different cancers is discussed in the ensuing chapters dedicated to individual cancer type.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"129 ","pages":"1-16"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy in Glioblastoma. 胶质母细胞瘤的免疫治疗。

Cancer treatment and research Pub Date : 2025-01-01 DOI: 10.1007/978-3-031-97242-3_6

Andrew Williams, Rimas V Lukas

引用次数: 0

Immunotherapy in Head and Neck Cancer. 头颈癌的免疫治疗。

Cancer treatment and research Pub Date : 2025-01-01 DOI: 10.1007/978-3-031-97242-3_7

Bridget E Crossman, Regan L Harmon, Mari Iida, Candie Y Lin, Jennifer Yoon, Evan P Pisick, Ravi Salgia, Tiffany Glazer, Randall Kimple, Justine Yang Bruce, Deric Wheeler

引用次数: 0

Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives. 免疫治疗在卵巢癌中的作用：进展、挑战和未来展望。

Cancer treatment and research Pub Date : 2025-01-01 DOI: 10.1007/978-3-031-97242-3_10

Pankaj Garg, Gargi Singhal, Siddhika Pareek, Ajaz Khan, TingTing Tan, Deric Wheeler, Sharad S Singhal

{"title":"Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives.","authors":"Pankaj Garg, Gargi Singhal, Siddhika Pareek, Ajaz Khan, TingTing Tan, Deric Wheeler, Sharad S Singhal","doi":"10.1007/978-3-031-97242-3_10","DOIUrl":"10.1007/978-3-031-97242-3_10","url":null,"abstract":"Ovarian cancer (OC) remains one of the most challenging gynecologic malignancies due to its late-stage diagnosis, high recurrence rates, and limited survival outcomes. Immunotherapy has emerged as a transformative approach in cancer treatment, leveraging the immune system to target tumor cells. This chapter provides a comprehensive overview of immunotherapy in OC, discussing its mechanisms, key strategies, and clinical advancements. Key areas include the role of immune checkpoint inhibitors (ICIs), adoptive cell therapies (ACT), cancer vaccines, and oncolytic viruses. Despite promising preclinical and clinical outcomes, significant challenges persist, including low immunogenicity, resistance mechanisms, and immune-related adverse events. Strategies to address these barriers, such as combination therapies, biomarker-guided approaches, and the integration of artificial intelligence (AI) for personalization, are discussed. Emerging directions, including next-generation immune checkpoint targets and innovations in epigenetic and metabolic reprogramming, are explored to envision the future of immunotherapy in OC. By addressing these challenges and leveraging innovative strategies, immunotherapy has the potential to redefine the therapeutic landscape, improving survival and quality of life for patients with OC.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"129 ","pages":"187-220"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing Prostate Cancer Treatment: Innovations and Challenges in Immunotherapy. 推进前列腺癌治疗：免疫治疗的创新与挑战。

Cancer treatment and research Pub Date : 2025-01-01 DOI: 10.1007/978-3-031-97242-3_12

Gargi Singhal, Pankaj Garg, Atish Mohanty, Sudarsan Vishnu Kollimuttathuillam, Deric Wheeler, Bamidele A Adesunloye, Sharad S Singhal

{"title":"Advancing Prostate Cancer Treatment: Innovations and Challenges in Immunotherapy.","authors":"Gargi Singhal, Pankaj Garg, Atish Mohanty, Sudarsan Vishnu Kollimuttathuillam, Deric Wheeler, Bamidele A Adesunloye, Sharad S Singhal","doi":"10.1007/978-3-031-97242-3_12","DOIUrl":"10.1007/978-3-031-97242-3_12","url":null,"abstract":"Prostate cancer (PCa), a leading cause of cancer mortality in men, has experienced a paradigm shift with the rise of immunotherapy. This chapter examines the immunological landscape of PCa and highlights key immunotherapeutic approaches, including cancer vaccines, immune checkpoint inhibitors (ICIs), adoptive cell therapies, and cytokine-based treatments. Emerging innovations, such as oncolytic viruses, neoantigen-based therapies, and bispecific antibodies, are also examined. Challenges like the immunosuppressive tumor microenvironment (TME), limited predictive biomarkers, and immune-related adverse events (irAEs) are addressed, alongside promising combination strategies with androgen deprivation therapy (ADT), radiotherapy, and targeted therapies. Advances in biomarker discovery and artificial intelligence (AI) are emphasized for their role in optimizing personalized immunotherapy. This chapter underscores the need for equitable access to these advancements and concludes with a vision for integrating immunotherapy into standard care, offering durable and transformative outcomes for PCa patients.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"129 ","pages":"267-291"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Advancements in Immunotherapy for the Treatment of Metastatic Breast Cancer. 免疫治疗转移性乳腺癌的最新进展。

Cancer treatment and research Pub Date : 2025-01-01 DOI: 10.1007/978-3-031-97242-3_3

B Madhu Krishna, Pankaj Garg, Sravani Ramisetty, Meera Nair, Sharad S Singhal

{"title":"Recent Advancements in Immunotherapy for the Treatment of Metastatic Breast Cancer.","authors":"B Madhu Krishna, Pankaj Garg, Sravani Ramisetty, Meera Nair, Sharad S Singhal","doi":"10.1007/978-3-031-97242-3_3","DOIUrl":"10.1007/978-3-031-97242-3_3","url":null,"abstract":"Breast cancer (BC) is the most prevalent malignancy among women in the United States, affecting approximately 13% of the female population. While advancements in treatment strategies have improved survival rates, significant challenges remain due to tumor heterogeneity, metastatic progression, and acquired resistance to therapy. Recent studies have highlighted the potential of immunotherapy in managing various solid tumors, including BC. This growing interest stems from increasing recognition of the immune system's role in both normal breast tissue and BC development, leading to extensive clinical investigations into BC immunotherapy and its tumor immune landscape. Despite its promise, immunotherapy for BC faces hurdles such as low tumor immunogenicity, inadequate T-cell infiltration, and a highly immunosuppressive tumor microenvironment (TME), which limit its efficacy. Among the available approaches, PD-1/PD-L1 inhibitors have shown clinical benefit in a subset of metastatic BC patients, particularly those with PD-L1-positive tumors, triple-negative BC (TNBC), or high tumor-infiltrating lymphocyte (TIL) levels. Notably, atezolizumab and pembrolizumab have demonstrated durable responses in metastatic TNBC, underscoring their therapeutic potential. Current research is focused on developing combination immunotherapy strategies that can overcome resistance, enhance response rates, and convert non-responders to therapy-sensitive cases. A key area of investigation involves identifying biomarkers that can predict immunotherapy responsiveness, guide salvage therapy in progressive disease, and optimize personalized treatment combinations. This review explores the latest advancements and future directions in BC immunotherapy, including novel combination strategies with vaccines and chemotherapeutics aimed at improving treatment efficacy and patient survival outcomes.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"129 ","pages":"33-65"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pancreatic Cancer Immunotherapy: A Team-Based Approach. 胰腺癌免疫治疗：一种基于团队的方法。

Cancer treatment and research Pub Date : 2025-01-01 DOI: 10.1007/978-3-031-97242-3_11

Krushangi Patel, Percy Lee, Julius Weng, Laleh Melstrom, Mustafa Raoof, Aaron Lewis, Vincent Chung

引用次数: 0

A NSQIP-Based Randomized Clinical Trial Evaluating Choice of Prophylactic Antibiotics for Pancreaticoduodenectomy. 一项基于 NSQIP 的随机临床试验，评估胰十二指肠切除术中预防性抗生素的选择。

Cancer treatment and research Pub Date : 2024-01-01 DOI: 10.1007/978-3-031-61238-1_7

Brian C Brajcich, Clifford Y Ko, Jason B Liu, Ryan J Ellis, Michael I D'Angelica

{"title":"A NSQIP-Based Randomized Clinical Trial Evaluating Choice of Prophylactic Antibiotics for Pancreaticoduodenectomy.","authors":"Brian C Brajcich, Clifford Y Ko, Jason B Liu, Ryan J Ellis, Michael I D'Angelica","doi":"10.1007/978-3-031-61238-1_7","DOIUrl":"10.1007/978-3-031-61238-1_7","url":null,"abstract":"Surgical site infection is a common complication following pancreaticoduodenectomy and is a major source of postoperative morbidity. Surgical site infection is more common among patients who undergo preoperative biliary instrumentation, likely because of the introduction of intestinal flora into the normally sterile biliary tree. Frequently, bacterial isolates from surgical site infections after pancreaticoduodenectomy demonstrate resistance to the antibiotic agents typically used for surgical prophylaxis, suggesting that broad-spectrum coverage may be beneficial. This chapter summarizes the current evidence regarding surgical site infection following pancreatic surgery and describes the rationale and methodology underlying a multicenter randomized trial evaluating piperacillin-tazobactam compared with cefoxitin for surgical site infection prevention following pancreaticoduodenectomy. As the first U.S. randomized surgical trial to utilize a clinical registry for data collection, this study serves as proof of concept for registry-based clinical trials. The trial has successfully completed patient accrual, and study results are forthcoming.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"192 ","pages":"131-145"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathologic Features of Primary Colon, Rectal, and Anal Malignancies. 原发性结肠、直肠和肛门恶性肿瘤的病理特征。

Cancer treatment and research Pub Date : 2024-01-01 DOI: 10.1007/978-3-031-61238-1_12

Kusum Sharma, Kaitlin E Sundling, Ranran Zhang, Kristina A Matkowskyj

引用次数: 0

Environmental and Genetic Risk Factors for Gastric Cancer. 胃癌的环境和遗传风险因素。

Cancer treatment and research Pub Date : 2024-01-01 DOI: 10.1007/978-3-031-61238-1_1

Dhavan Shah, David Bentrem

引用次数: 0